-transparent.png){kind=logo}
Cultured P388/VCR mouse lymphoma cells resistant to vincristine (VCR) and to 5-bromodeoxyuridine (BUdR) and deficient in thymidine kinase (TK-) were fused with P388/DAG cells resistant to 1.2:5,6-dianhydrogalactitol (DAG), an anticancer alkylating agent, and to 6-thioguanine (6-TG) and deficient in hypoxanthine phosphoribosyl-transferase (HPRT-). The hybrid cells expressed multidrug resistance (MDR), i.e., resistance to VCR and cross-resistance to Adriamycin (ADM) and actinomycin D (Act. D), in a dominant manner. The presence of glycoprotein p170, the MDR gene product, was detected in the hybrid cells. Resistance to DAG was also expressed dominantly, whereas cross-resistance to dibromodulcitol (DBD), a chemically related anticancer drug, was slight.
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
January 1993,
Journal of the National Cancer Institute,
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
October 2010,
Anticancer research,
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
March 1999,
Biophysical chemistry,
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
March 2001,
Mechanisms of ageing and development,
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
September 2000,
American journal of veterinary research,
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
June 1990,
Proceedings of the National Academy of Sciences of the United States of America,
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
January 1980,
Immunogenetics,
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
January 2000,
Anticancer research,
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
May 1999,
Cancer,
I Pályi, and
G Turi, and
L Hullán, and
K Szikla, and
M Bak
January 2003,
In vivo (Athens, Greece),
